If you have been newly diagnosed with acute myeloid leukemia (AML), the QuANTUM-First Study may be an option for you. The study is evaluating an investigational medication for AML, given in addition to chemotherapy.To learn more or to see if you qualify
QuANTUM-First is a clinical trial for newly diagnosed patients with AML who also have a genetic mutation known as FLT3-ITD. The purpose of this study is to compare the effect of quizartinib (an investigational medication) in combination with standard chemotherapy versus standard chemotherapy alone.
If you qualify and participate in this study, you will receive standard of care treatment. This graphic shows the three phases of treatment in the clinical trial.
(up to 2 cycles)
GOAL: Reduce cancer cells
(up to 4 cycles of chemotherapy, transplant allowed)
GOAL: Further reduce cancer cells
(up to 12 cycles)
GOAL: Maintain remission and prevent relapse
Participating in the QuANTUM-First Study will not interfere with your ability to receive a stem cell transplant.